Cerebral blood flow (CBF) rises when the glucose supply to the brain is limited by hypoglycemia or glucose me tabolism is inhibited by pharmacological doses of 2-deoxyglu cose (DG). The present studies in unanesthetized rats with in sulin-induced hypoglycemia show that the increases in CBF, measured with the e4C]iodoantipyrine method, are relatively small until arterial plasma glucose levels fall to 2.5 to 3.0 mM, at which point CBF rises sharply. A direct effect of insulin on CBF was excluded; insulin administered under euglycemic conditions mS.intained by glucose injections had no effects on CBF. Insulin administration raised plasma lactate levels and decreased plasma K+ and HC03 -concentrations and arterial pH. These could not, however, be related to the increased CBF because insulin under euglycemic conditions had similar ef-
fects without affecting CBF; furthermore, the inhibition of brain glucose metabolism with pharmacological doses (200 mglkg intravenously) of DG increased CBF, just like insulin hypoglycemia, without altering plasma lactate and K+ levels and arterial blood gas tensions and pH. Nitric oxide also does not appear to mediate the increases in CBF. Chronic blockade of nitric oxide synthase activity by twice daily i.p. injections of N G -nitro-L-arginine methyl ester for 4 days or acutely by a single i.v. injection raised arterial blood pressure and lowered CBF in normoglycemic, hypoglycemic, and DG-treated rats but did not significantly reduce the increases in CBF due to insulin induced hypoglycemia (arterial plasma glucose levels, 2.5-3 mM) or pharmacological doses of deoxyglucose. Key Words: Insul in-[ 14C J Iodoantipyrine-Nitric oxide-Glucopri vation. Bryan et aI., 1987; !chord et aI., 1994) . The discrepant results may have been due to species differences, the presence or absence of anesthesia, the nutritional state of the animals, the level and duration of hypoglycemia, or differences in the methods employed to determine CBF. In all studies in which it was determined, cerebral energy metabolism, for example, cerebral oxygen consumption (CMR02) or glucose utilization (CMR g1c ), was reduced during insulin-induced hypoglycemia, the number of structures affected, and the extent of reductions in me tabolism varying with the severity of the hypoglycemia (Kety et aI., 1948; Eisenberg and Seltzer, 1962; Norbert and Siesjc), 1976; Ratcheson et aI., 198 1; Ghajar et aI., 1982; Suda et aI., 1990) .
The mechanism responsible for the increased blood flow is unknown, but it is of interest that pharmacologi cal doses of 2-deoxyglucose, which produce clinical ef fects like those of insulin-induced hypoglycemia despite elevated blood glucose levels (Landau et aI., 1958) , also cause marked increases in local CBF throughout the brain in unanesthetized animals (Breier et aI., 1993) . This would suggest that neither direct action of insulin nor the blood glucose level per se is responsible.
A vasodilator agent derived from vascular endothe lium, the endothelium-derived relaxing factor (EDRF), has been shown to mediate the vasodilator effects of acetylcholine (Furchgott and Zawadzki, 1980) . This fac tor has been identified as nitric oxide (NO) (Palmer et aI., 1987; Ignarro et aI., 1987) . Nitric oxide is enzymatically produced in brain tissue and vascular endothelium, and it mediates the effects of a number of vasodilator drugs and plays a role in the regulation of systemic blood pressure and vascular tone (Ignarro, 1989; Moncada et a!., 199 1) . It also provides a tonic vasodilator influence on the ce rebral circulation; inhibition of its synthesis reduces ce rebral blood flow throughout the brain despite an eleva tion in mean arterial blood pressure (MABP) (Sokoloff et a!., 1992; Adachi et aI., 1994) . Inhibition of NO synthase activity has also recently been reported to attenuate the increases in CBF during insulin-induced hypoglycemia in anesthetized, mechanically ventilated piglets, suggest ing that NO plays a role in mediating the cerebrovascular response to hypoglycemia (!chord et a!., 1994) .
In the present studies, we examined the effects of in sulin-induced hypoglycemia and pharmacological doses of 2-deoxyglucose on CBF. Both modes of producing cerebral glucoprivation result in increases in CBF, de-( spite major differences in systemic effects. By comparing their effects, we have been able to eliminate several possible mechanisms responsible for the cerebral vaso dilator effects, for example, a direct action of insulin as well as some of the systemic effects of insulin, including those on blood constituents. We have also examined and found no evidence to support a role for nitric oxide in the mediation of the increases in CBF during glucoprivation. 
MATERIALS AND METHODS

Chemicals
Animals
All procedures performed on animals were in strict accor dance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the local animal care and use committee. Normal adult male Sprague Dawley rats weighing 270 to 380 g were obtained from Taconic Farms (Germantown, NY, U.S.A.) and maintained in a climate controlled room on a normal 12 h light/dark cycle with food and water available ad libitum. The rats were fasted but allowed free access to water for about 16 h immediately before the experiment. On the day of the experiment, the rat was anesthe-tized with halothane (5% for induction and 1.0-1.5% for main tenance) in 70% N20/30% °2, and polyethylene catheters (PE 50, Clay-Adams, Parsippany, NJ, U.S.A.) were inserted into both femoral arteries and one femoral vein. One arterial cath eter was used for continuous recording of arterial blood pres sure, and the other was standardized at exactly 16 cm long and used for sampling of arterial blood; the venous catheter was used for injection of agents and tracers. A loose-fitting plaster cast was then applied to the lower abdomen and hips and taped to a lead brick to prevent locomotion. Body temperature was continuously monitored by a rectal probe and maintained at 37°C by thermostatically controlled heating lamps. At least 3 h were then allowed for recovery from the effects of the surgery and anesthesia before continuation of the experimental proce dure.
Physiological variables
We monitored MABP with a blood-pressure analyzer (Mi 
Measurement of local cerebral blood flow
Local CBF was determined by the autoradiographic [14C] iodoantipyrine method as previously described (Sakurada et aI., 1978) , modified only by the use of a programmed i.v. infusion to obtain a constantly rising tracer concentration in the arterial blood (i.e., ramp input function). Local CBF was computed by means of the operational equation of the [14C]IAP method with appropriate corrections for the lag and washout of the dead space in the arterial sampling catheter (Frerichs et aI., 1994) ; arterial catheter flow rates per minute were adjusted to equal at least 40 dead space volumes per minute to minimize the mag nitude of the corrections. Average rates of blood flow for the brain as a whole, weighted appropriately for the relative sizes 
Experimental procedures
The experiments were designed to characterize and examine the possible mechanisms of the effects of glucoprivation on CBF induced by insulin and also by pharmacological doses of DG. Therefore, in all the experiments, a variety of physiologi cal variables appropriate to the condition being studied were examined 3 h after recovery from the anesthesia, at various times during the establishment of the glucoprivic state, and always immediately before the determination of local CBF. In all cases, arterial plasma glucose concentration and arterial blood gas tensions and pH were measured at IS-min intervals after administration of either insulin or DG and again immedi ately before the procedure for measuring CBF.
Effects of insulin-induced hypoglycemia on CBF. Thirty rats were given i.v. injections of 0.125 to 15 Ulkg insulin to achieve a range of levels of hypoglycemia; 15 control rats were admin istered comparable volumes of physiological saline alone. The procedure for measuring CBF was carried out 30 min after the insulin or saline administration. The dosage of insulin and the timing of the measurement of CBF after its administration were chosen on the basis of the results of preliminary experiments to establish the conditions needed to lower arterial plasma glucose concentrations into the 2 to 6 mM range without producing seizures, coma, or significant changes in arterial blood gas tensions and pH that could influence CBF.
Effects of insulin on CBF in euglycemic rats. In seven rats, insulin (10 U/kg) , immediately followed by 2.5 ml of a 10% (wtlvol) solution of glucose, was injected intravenously and this was usually sufficient to maintain euglycemia, but in a few rats it was necessary to inject an additional I ml of the 10% glucose solution to keep the plasma level from falling below 5.5 mM. Seven control rats for this group received no insulin but about the same volume of physiological saline in place of the insulin and 10% glucose solution. The procedure for mea suring CBF was initiated 30 min after the administration of the insulin or saline.
Effects of pharmacological doses of2-deoxyglucose on CBF.
Six rats were given 200 mg/kg of a 10% (wtlvol) aqueous solution of DG intravenously; six control rats were given equivalent volumes of physiological saline. CBF was deter mined 15 min after the injections.
Effects of inhibition of nitric oxide synthase on the CBF response to glucoprivation. To examine the possibility that NO was involved in the mechanism of the cerebrovascular response to glucoprivation, the effects of acute and chronic inhibition of NO synthase 3ctivity on the changes in CBF elicited by glu coprivation were examined. For chronic inhibition, the rats were injected intraperitoneally twice daily for 4 consecutive days with 50 mg/kg ofL-NAME. This regimen was reported to inhibit NO synthase activity in the brain almost completely (Dwyer et aI., 1991) , and we have confirmed that it inhibits brain NO synthase activity by at least 85% (Adachi et aI., 1994) . Twenty-five rats pretreated in this manner received i.v. injections of 0.25 to 20 U/kg of insulin 16 to 18 h after the last dose of L-NAME, and CBF was measured 30 min after the insulin injection. Twenty-two rats, pretreated similarly with saline instead of L-NAME, also made hypoglycemic with in sulin as described above, served as controls for the effects of L-NAME in the presence of insulin-hypoglycemia.
Five rats chronically treated with L-NAME as described above were injected with pharmacological doses of i.v. DG (200 mg/kg) 16 to 18 h after the last dose ofL-NAME, and CBF was measured 15 min after DG administration. Six rats simi larly pretreated with L-NAME but given saline instead of DG were studied as controls for the effects of DG in the L-NAME treated rats. Six rats, pretreated with saline instead of L-NAME and given DG and six rats pretreated with saline and given saline instead of DG were studied as controls for the effects of DG in the absence of L-NAME pretreatment.
For acute inhibition of NO synthase activity, six rats were infused intravenously with a dose of 30 mg/kg of L-NAME in 1.2 to 1.5 ml of normal saline over a 1-to 1.5-min period. Six control rats received similar infusions of normal saline alone.
Fifteen minutes after the L-NAME infusion, 10 to 20 U of insulin were administered intravenously to three of the rats and saline to the other three, and arterial plasma glucose concen tration and MABP were monitored. Similar experiments were carried out in six other rats, three administered 200 mg/kg of DG 30 min after L-NAME administration and three given saline instead of DG; CBF was measured 15 min later. In accor- 1997 dance with the reported time-dependence of the effect of L NAME on NO synthase activity (Iadecola et aI., 1994) , the measurement of CBF was initiated 45 min after the L-NAME administration when the degree of inhibition is close to its maximum. In all cases, MABP had reached a maximum at 10 to 15 min after the L-NAME administration and remained close to that level at the time of the measurement of CBF.
Effects of insulin-induced hypoglycemia and deoxyglucose loading on the EEG. It was not feasible to obtain EEG tracings in the rats prepared for the determination of CBF. Therefore, EEG recordings were made in separate groups of rats. The EEG was recorded in one group of four rats made hypoglycemic with insulin like those in which CBF was determined, (i.e., 2.1 to 5.6 mM glucose in arterial plasma) and in another two rats given pharmacological doses of DG (200 mg/kg). These rats had been previously prepared by the placement of brass screws biparietally in the calvarium that served as electrodes for bipo lar recording.
RESULTS
Effects of insulin-induced hypoglycemia and deoxyglucose loading on EEG
In the four animals made hypoglycemic by insulin, the EEO pattern was monitored continuously from the time of injection of the insulin until the arterial plasma glu cose level had reached 2.0 mM. Thirty minutes after injection of the insulin, when the procedure for measur ing CBF was ordinarily initiated, the EEO pattern was either unchanged from that before the insulin adminis tration or displayed minimal slowing. All the rats exhib ited progressive reductions in spontaneous activity with increasing hypoglycemia, but they all remained respon sive to tactile and auditory stimuli. The administration of 200 mg/kg of DO intravenously also produced little if any change in the EEO; there was some reduction in spontaneous activity with preservation of responses to tactile and auditory stimulation.
Effects of insulin-induced hypoglycemia on physiological variables and CBF
Insulin-treated rats with hypoglycemia in the range of 2.6 to 5.6 mM arterial plasma glucose levels showed reduced arterial blood pH and plasma K+ concentrations and a rise in arterial plasma lactate concentration (p < 0.05, analysis of variance [ANOYA] and Dunnett's t test) (Table 1) . Further reductions in plasma pH and K+ concentration and increases in lactate concentration oc curred in more severe hypoglycemia (2. 1-2.5 mM glu cose) (p < 0.0 1, ANOYA and Dunnett's t test). Arterial HC03 -concentrations were statistically significantly re duced by hypoglycemia but only by about 4% from con trol levels (Table 1) . Arterial P02 remained in the normal range in both mild and moderate hypoglycemia although it was slightly but statistically significantly higher in the mild hypoglycemic than in the control rats (Table 1) . The CBF tended to rise slightly but progressively with de clining arterial plasma glucose levels from 8.8 mM to about 2.5 mM, but CBF rose precipitously when glucose 
Mean arterial blood pressure (mm Hg) 120 ± 10
Poo2 (mm Hg)
± 4
Paco2 (mm Hg) 38 ± 2 Arterial pH 7.42 ± 0.02
Arterial blood HC03 -concentration (mM) Arterial plasma glucose concentration (mM) Arterial plasma K+ concentration (mM) Arterial plasma lactate concentration (mM)
Values are means ± SD calculated from the numbers of animals in parentheses.
"p < 0.05. e p < 0.01, compared with the saline-treated controls (ANOVA followed by Dunnett's t test for multiple comparisons).
levels fell to about 2.5 mM and reached rates about twice normal at 2. 1 mM (Fig. 1 ). This same pattern of increas ing CBF with declining plasma glucose concentration was observed in virtually all 26 regions of the brain that were examined; six such structures representative of various neural systems are presented in Fig. 2 .
Effects of insulin on physiological variables and CBF in euglycemic rats
To determine whether the effects of insulin on CBF were direct or a secondary consequence of the hypogly cemia, the effects of insulin administration on CBF in rats maintained in a euglycemic state were examined. A high dose of insulin (10 U/kg) was used in these studies, but the arterial plasma glucose level was monitored and maintained more or less euglycemic by simultaneous in- jections of glucose as needed. In these euglycemic rats, insulin had the same effects on plasma constituents as it did in the hypoglycemic rats, for example, slight reduc tions in arterial blood pH and HC03 -concentration, a pronounced reduction in plasma K+ concentration, and a greater than 50% rise in plasma lactate concentration (Table 2 ). In the hyperinsulinemic euglycemic rats aver age CBF in the brain as whole was not statistically sig nificantly different from the values in the control rats administered saline rather than insulin (Fig. 3) , indicat ing that it was not insulin per se but the hypoglycemia that caused the increases in CBF seen in hypoglycemia. These results are in agreement with those of Duckrow (1988) , who also found no effects of insulin on CBF under euglycemic conditions.
Effects of pharmacological doses of deoxyglucose on physiological variables and CBF
Cerebral glucoprivation was also induced by the i.v. administration of 200 mg/kg of DG. Fifteen minutes after the injection, plasma glucose levels had risen signifi cantly, arterial Paco2 increased from 37 to 42 mm Hg, and arterial pH fell from 7.42 to 7.36; arterial HC03-, K+, and lactate concentrations, however, remained un changed (Table 3) . Measured 15 min after the DG injec tion, CBF was found to be 20 1 ml 100 g-l min-I , almost double the value of 110 ml 100 g-I min-1 found in the control rats that had received saline.
Systemic effects ofL-NAME
Intravenously administered L-NAME (30 mg/kg) raised MABP in every rat. In L-NAME-treated rats not subsequently subjected to glucoprivation, MABP rose from a baseline level of 123 ± 6 (mean ± SD) to 145 ± 8 mm Hg (n = 6, p < 0.0002 by paired t test) at the time of the measurement of CBF. The acute L-NAME admin istration raised MABP from a baseline mean of 125 ± 1 to 155 ± 5 mm Hg (n = 3, p < 0.0 1 by paired t test) in the group subsequently treated with insulin and from 129 ± 14 to 149 ± 10 in the DG-treated rats (n = 3, p < 0.05 by paired t test). None of the other physiological vari ables that were measured was significantly affected by the acute L-NAME administration.
The twice-daily i.p. injections of L-NAME for 4 days also had no significant effects on the measured physi ological variables, except for increases in MABP to lev els like those after acute L-NAME administration. In the e group subsequently treated with insulin, MABP was 158 ± 8 mm Hg (mean ± SD) in the 25 rats chronically ( ±SD) in the brain as a whole in saline-treated control and insulin-treated eu glycemic rats. The rats that received insulin were also given i.v. injections of 10% glucose to maintain euglycemia. There was no statistically significant difference in CBF between the two groups by grouped t test. pretreated with L-NAME compared with 133 ± 10 mm Hg in the 22 control rats that did not receive the chronic L-NAME administration (p < 0.00 1, grouped t test). In rats given loading doses of DG, MABP was 149 ± 7 mm Hg in those treated with L-NAME (n = 5) compared with 127 ± 8 (n = 6) in the control rats (n = 6) that did not receive L-NAME (p < 0.00 1, grouped t test).
Effects of chronic L-NAME pretreatment on the CBF responses to insulin-induced hypoglycemia or
DG loading
Insulin-induced hypoglycemia. In agreement with the findings of Adachi et al. (1994) , chronic pretreatment with L-NAME tended to reduce CBF below the levels in the saline-pretreated control rats with arterial plasma glu cose concentrations in the 3 to 6 mM range (Fig. 4) . When the saline control rats (e.g., those treated with neither L-NAME nor glucoprivation) from both the in sulin-hypoglycemia ( Fig. 5 ) and DG-loading ( Fig. 6 ) studies were pooled and the same was done with the rats chronically treated with L-NAME but not subjected to glucoprivation, the reduction of CBF by chronic L NAME treatment was statistically significant (saline controls: mean ± SD = 106 ± 12, n = 21; L-NAME treated: mean ± SD = 96 ± 16, n = 13; P = 0.032 by grouped t test). When the plasma glucose level was re duced to 2 to 3 mM, CBF exhibited the same sharp rises in CBF in both the L-NAME-pretreated and saline pretreated rats; the percent increase in CBF above base line elicited by hypoglycemia was unaffected by the pre treatment with L-NAME, and there was no statistically significant interaction between the effects of L-NAME and hypoglycemia by two-way ANOV A (Fig. 5) .
Pharmacologic doses of DC. Chronic pretreatment with L-NAME raised MABP and tended to lower base line CBF below that of the saline-pretreated control rats, but it did not prevent the marked enhancement of CBF by DG loading. The percent increases in CBF were es sentially the same in both groups (Fig. 6) , and there was no significant interaction between the effects of L NAME treatment and DG loading (two-way ANOV A).
Effects of acute L-NAME administration on CBF responses to insulin-induced hypoglycemia or
Chronic pr e treatment with L-NAME has been shown to inhibit 85 to 95% of total brain NO synthase activity (D wyer et aI., 199 1; Adachi et aI., 1994) . The increases in MABP that we observed indicated that at least endo thelial NO synthase had been effectively inhibited. The results obtained with chronic L-NAME treatment there fore suggested that the cerebrovascular dilatation associ ated with insulin-induced hypoglycemia or blockade of cerebral glucose utilization by pharmacologic doses of DG is not mediated by NO. There have, however, been suggestions that compensatory mechanisms might come into play in the regulation of CBF during prolonged blockade of NO synthase activity (Wang et aI., 1994) . We therefore also examined the effects of acute admin- Effects of chronic (i.e., 50 mg/kg of L-NAME intraperito neally twice daily for 4 consecutive days) and acute (i.e., 30 mg of L-NAME intravenously 45 min before measurement of CBF)
inhibition of nitric oxide synthase activity on the responses of average whole brain blood flow (means ± SO) to insulin-induced hypoglycemia (arterial plasma concentration, 2.0-2.5 ml\tl). The effects of L-NAME on the CBF responses to hypoglycemia were not statistically significant (two-way analysis of variance, no in teraction between L-NAME treatments and hypoglycemia). 
Chronic Chronic
Acute Acute L-NAME L-NAME L-NAME L-NAME
Effects of chronic (50 mg/kg of L-NAME intraperitoneally twice daily for 4 consecutive days) and acute (30 mg of L-NAME intravenously 45 min before measurement of CBF) inhibition of nitric oxide synthase activity on the responses of average whole brain blood flow (means ± SO) to pharmacological doses of 2-de oxyglucose (200 mg/kg, i.v.) . The effects of L-NAME on the CBF response to Iill G loading was not statistically significant (two-way analysis of variance, i.e., no interaction between L-NAME treat ment and DG loading).
istration of L-NAME on the increases in CBF associated with insulin-hypoglycemia or DG loading. In control rats subjected to neither insulin-induced hy poglycemia nor DG loading, acute i.v. administration of L-NAME reduced CBF significantly, indeed, consider ably more than did chronic pretreatment with L-NAME; CBF was 106 ± 12 (mean ± SD) in the control rats (n = 21) and 66 ± 5 in the rats given acute doses of L-NAME (n = 6) (p < 0.000 1 by grouped t test). It did not, how ever, significantly alter the enhancement of CBF by hy poglycemia or DG loading (two-way ANOV A) (Figs. 5 and 6).
DISCUSSION
The results of previous studies on the effects of hypo glycemia on CBF have been inconsistent. The earliest quantitative studies in hypoglycemia were carried out in human subjects with the nitrous oxide method. In the first study by Kety et aI. (1948) on the effects of insulin shock treatment in schizophrenia, CBF was not signifi cantly altered when blood glucose concentrations were lowered from a control level of 74 (4. 1 mM) to 19 (1.1 mM) and then to 8 mg% (0.4 mM); the reduced glucose levels were, however, sufficient to cause profound re ductions in CMR02 and CMR g lc• Eisenberg and Seltzer (1962) , also using the nitrous oxide method, subse quently reported no statistically significant changes in CBF in human subjects despite reduced blood glucose concentrations from a mean of 85 (4.7 mM) to 31 (1.7 mM) mg% and a 32% fall in CMR g lc; surprisingly, they also observed a 16% increase in CMROz, which they speculated was due to an epinephrine release into the blood. In another group of subjects in which blood glu cose concentration was lowered from 10 1 (5.6 mM) to 51 mg% (2.8 mM), no significant changes occurred in CBF, CMR02 or CMR g lc• In contrast, in schizophrenic patients in insulin-induced coma studied with the same method, Della Porta et aI. (1964) found a 50% increase in CBF, a 57% decrease in CMR g 1c' and no significant change in CMR02• Studies of local CBF in rats with the ( 4 C]iodoanti pyrine method have provided more uniform results. In anesthetized, paralyzed, artificially ventilated rats, local CBF was markedly increased in most regions of brain during insulin-induced hypoglycemia (e.g., blood glu cose level, 1.26 mM) severe enough to produce slow wave poly-spike activity in the EEG (Abdul-Rahman et aI., 1980); CBF increased several fold above control lev els when the hypoglycemia was accompanied by an iso electric EEG (Abdul-Rahman et aI., 1980; Siesjo et aI., 1983) . In awake, restrained rats Bryan et aI. (1987) found that moderate hypoglycemia (e.g., plasma glucose level, 2.6 mM) increased local CBF in some regions of the brain (e.g., in the cerebral cortex and basal ganglia but not in the hypothalamus and cerebellum); more severe hypoglycemia (plasma glucose level, 1.5 mM) caused even greater increases in local CBF throughout the brain, including the hypothalamus and cerebellum.
The reasons for the differences in the results of these various studies are unclear, but variations in the severity of the hypoglycemia, the presence or absence of seizure activity, differences in the methods employed to deter mine CBF, and possibly species differences may have been involved. It is clear, however, from most studies that hypoglycemia generally is associated with cerebral vasodilator influences that are often sufficient to increase CBF.
The results of the present studies demonstrate that hy poglycemia increases CBF in almost all regions of the brain, but the effect is strongly dependent on the degree of hypoglycemia. With lesser degrees of hypoglycemia in the range of arterial plasma glucose levels between approximately 3 and 9 mM, CBF tends to rise as the plasma glucose level declines, but it is slight and of doubtful significance. When arterial plasma glucose con centration falls below 2.5 to 3 mM, however, there is an abrupt and marked increase in CBF in almost all regions of the brain. This effect occurs at a rather moderate de gree of hypoglycemia because the animals, although sub dued, showed no loss of consciousness or EEG abnor-malities. It it of interest that the level of hypoglycemia at which the marked increase in CBF occurs is similar to the level at which glucose consumption in the brain be comes moderately depressed (Suda et aI., 1990) and ATP levels in brain begin to fall (Ghajar et aI., 1982) .
The nature of the cerebral vasodilator influences and the mechanism of the increase in CBF provoked by hy poglycemia are still unknown. A major goal of the pres ent study was to examine systematically the possible mechanisms that might apply. To do so, we compared the effects of two different paradigms of cerebral gluco privation, impairment of glucose supply to the brain by insulin-induced hypoglycemia or chemical blockade of cerebral glucose metabolism. Pharmacological doses of 2-deoxyglucose are known to produce a comatose state like that of hypoglycemia while at the same time raising blood glucose levels (Landau et aI., 1958) . The mecha nism of this effect is a blockade of glycolysis at the glucose-6-phosphate isomerase step (Wick et aI., 1957; Horton et aI., 1973) . Short of those that produce coma or seizures, DG loading doses have also been found to pro duce widespread and marked increases in CBF through out the brain (Breier et aI., 1993) . A reasonable assump tion is that the mechanisms underlying this effect are the same as those in hypoglycemia. The comparison has led to the exclusion of a number of possible mechanisms.
Insulin ad k inistration results not only in lower blood glucose levels but also lower plasma K+ and increased lactate concentrations and a small decline in arterial pH. Insulin, administered together with glucose to maintain euglycemic conditions, produces essentially the same changes in blood and plasma without altering CBF, and DG loading raises CBF like insulin-induced hypoglyce mia without those changes in blood and plasma, except for the change in blood pH. These results exclude the changes in blood or plasma lactate and K+ concentrations or blood pH and a direct action of insulin as the possible causes of the increased CBF during glucoprivation.
Nitric oxide has been identified as the EDRF which mediates acetylcholine-induced vasodilatation (Furch gott and Zawadzki, 1980; Palmer et aI., 1987; Moncada et aI., 199 1) . A possible role of NO in the increases in CBF during cerebral glucose deprivation was, therefore, investigated. Nitric oxide is produced in vascular endo thelium and in neurons and glia by oxidation of arginine catalyzed by the enzyme nitric oxide synthase. The total activity of this enzyme in brain has been shown in rats to be almost completely inhibited by twice daily injections of 50 mg/kg of L-NAME for 4 days (Dwyer et aI., 199 1; Adachi et aI., 1994) . We used this regimen to prevent the formation of NO in both the endothelium and the brain cells. To avoid the influence of possible compensatory mechanisms during prolonged NO synthase inhibition, we also examined the effects of acute inhibition by a single i.v. dose of L-NAME shortly before the measure- Vol. 17, No. I, 1997 ment of CBF. In both cases, the enhancement of CBF by hypoglycemia or pharmacological doses of DG was un affected by the NO synthase inhibition. This result is partly in contrast to that of Ichord et aI. (1994) , who used the radiolabeled microsphere technique for determining CBF in 7 to lO-day-old piglets under anesthesia; they observed that inhibition of NO synthase activity did at tenuate but did not eliminate the enhancement of CBF by hypoglycemia in forebrain, cortical gray matter, and cer ebellum, but it had no effects on the responses in the brain stem, thalamus, caudate, and hippocampus. It should be noted, however, that the degree of hypoglyce mia that they examined was profound enough for the EEG to become isoelectric. It is therefore difficult to compare their results with ours, which indicate that NO does not mediate the increases in CBF that we observe in unanesthetized rats with more moderate degrees of hy poglycemia.
Glucoprivation, whether induced by hypoglycemia or blockade of glucose metabolism with pharmacological doses of DG, is a stress that activates the sympathetic nervous system and raises blood epinephrine levels. Hollinger and Bryan (1987) concluded that adrenergic f)-receptors mediate the increase in CBF during hypo glycemia because the effect appeared to be partially at tenuated by the f)-blocker propranolol. More recently, Bryan et aI. (1994) found that the rise in plasma cate cholamine levels was temporally dissociated from the increase in CBF and could not, therefore, be responsible for the increased CBF in hypoglycemia. Noradrenergic effects of stress are unlikely to be involved because in creases in blood norepinephrine levels (King et aI., 1952) and intracerebral noradrenergic mechanisms have been shown to produce cerebral vasoconstriction (Kuschinsky and Wahl, 1978) as long as the blood-brain barrier re mains intact (Edvinsson et aI., 1993) . Studies in progress in our laboratory indicate that i.v. infusion of epinephrine that raise plasma epinephrine levels in normoglycemic rats to the same levels found in hypoglycemia have no effects on local or overall blood flow or glucose utiliza tion in the brain.
It may be of significance that CBF begins to rise sharply in unanesthetized rats when arterial plasma glu cose levels fall to about 2.5 to 3.0 mM. These are the levels at which local CMR g 1c begins to fall, particularly in structures with normally high rates, and brain ATP levels are not maintained (Ghajar et aI., 1982; Bryan et aI., 1986; Suda et aI., 1990) . This association suggests that the response of the cerebral vasculature may be re lated to limitations in the rate of glucose metabolism needed to maintain normal levels of ATP. Such a con dition would result in increases in brain adenosine levels which, in fact, have been observed in hypoglycemia (Chapman et aI., 198 1; Van Wylen et aI., 1989) , and adenosine is known to have cerebral vasodilator effects (Berne et aI., 1974) . We are currently exammmg the possibility that adenosine may play an important role in the cerebral vasodilatation associated with glucopriva tion. The results thus far indicate that caffeine, an aden osine receptor antagonist, attenuates in a dose-dependent fashion the increase in CBF seen in hypoglycemia.
The present studies have excluded blood pH, P acob p a02' and HC03 -concentration, plasma lactate and K+ concentrations, a direct action of insulin, and NO as criti cal factors in the mechanism of the enhancement of CBF during glucoprivation. Preliminary results of studies in progress suggest that epinephrine is also not involved but that adenosine may play a role.
